Alectinib is a 2nd generation highly selective anaplastic lymphoma kinase (ALK) inhibitor. Although alectinib has improved progression-free survival (PFS) in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC), there are limited treatment options after progression of alectinib. Recent evidences have described promising results of the combination of bevacizumab with EGFR-TKIs, cytotoxic chemotherapies and immune-checkpoint inhibitors. We report the results from a phase II study of the combination of alectinib with bevacizumab in ALK-positive Nonsquamous NSCLC patients who were treated with alectinib and showed disease progression (UMIN 000017828) READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.08.676
Authors: S. Watanabe, N. Matsumoto, J. Koshio, A. Ishida, T. Tanaka, T. Abe, D. Ishikawa, S. Shoji, K. Nozaki, K. Ichikawa, R. Kondo, A. Otsubo, A. Aoki, T. Kajiwara, K. Koyama, S. Miura, H. Yoshizawa, T. Kikuchi